Trastuzumab is the biosimilar version of Herceptin®, and the monoclonal antibody that associated with the HER2/neu receptor.
Trastuzumab created a major impact on the treatment toward HER2-positive metastatic breast cancer and HER2 positive metastatic gastric cancer. The combination of trastuzumab with chemotherapy has shown the elevated both the survival and response rates.
The cell line development and similarity study of trastuzumab are completed. We are looking for partner for co-development or licensee for marketing and sales.